Video

San Antonio Roundtable, Part 2: CALOR Trial, Triple-Negative Breast Cancer


 

Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at Thursday's sessions of 2012 San Antonio Breast Cancer Symposium, including the CALOR trial, in which chemotherapy prolonged survival for isolated local or regional recurrence of breast cancer; use of neoadjuvant chemotherapy in patients 35 years of age or younger; and profiling triple-negative breast cancers.

Recommended Reading

Surviving breast cancer shouldn't mean relinquishing intimacy
MDedge Hematology and Oncology
Breast Cancer: Molecular Profiling Doesn't Trump Standard Pathology
MDedge Hematology and Oncology
San Antonio Roundtable, Part 1: Fulvestrant Dose and Tamoxifen Duration
MDedge Hematology and Oncology
Experimental Drug Puts ER-Positive Breast Cancer on Hold
MDedge Hematology and Oncology
Less Invasive Biopsy Used Less in Black Breast Cancer Patients
MDedge Hematology and Oncology
Doubling Fulvestrant Dose Extends Breast Cancer Survival
MDedge Hematology and Oncology
Ten Years of Adjuvant Tamoxifen Found Superior to Five
MDedge Hematology and Oncology
Bevacizumab Adds No Progression, Survival Benefits to Estrogen Therapy
MDedge Hematology and Oncology
Mammograms Dip in Wake of USPSTF Recommendations
MDedge Hematology and Oncology
ONC-CHAT - What Did You Learn at the Meeting Today?
MDedge Hematology and Oncology